This is a preview of subscription content, log in via an institution to check access.
Reference
PHARMAC. Approval of decisions involving boceprevir and pegylated interferon with/without ribavirin. Internet Document : 9 Aug 2013. Available from: URL: http://www.pharmac.health.nz
Rights and permissions
About this article
Cite this article
NZ PHARMAC to fund boceprevir for hep C. PharmacoEcon Outcomes News 685, 11 (2013). https://doi.org/10.1007/s40274-013-0662-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0662-5